Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa

Aug 06 2012

• By Emily Hayes

Related Content

Amarin Version 3.0 Weighs Its Options on Promising Omega-3 Pipeline

Mar 14 2011

Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

May 14 2012

Amarin Aims <em>Vascepa </em>For The Sweet Spot Of Dyslipidemia

Jul 30 2012

Amarin Shuffles Management Again, But Says Omega-3 Trial Results Are Near

Nov 10 2010

Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?

Jan 26 2011

Related Companies

Amarin Corp plc

BASF AG

Omthera Pharmaceuticals, Inc.

Reliant Pharmaceuticals

Merck & Co., Inc.

Additional Topics

Clinical Trials Regulation Approvals

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window